Adenium Biotech ApS

Adenium Biotech ApS

Ole Maaløesvej 3
2200 - Copenhagen N



Phone: +45 7070 2980

Employees: 2-4


Name: Paul Goldenheim
Position: CEO

Development and commercialization of novel antibiotics for the treatment of multi drug resistant bacterial infections.

Adenium Biotech is a Danish biopharmaceutical company spun out from Novozymes A/S in 2011. Adenium focuses on the development and commercialization of novel antibiotics for the treatment of Gram-negative bacterial infections. Our focus is treatment of hospital acquired infections in particular complicated urinary tract infections and hospital acquired pneumonia caused by multiresistant Gram-negative bacteria. Complicated urinary tract infections are caused by predominantly Gram-negative bacteria and in particular Escherichia coli. E. coli is also a frequent cause of many other common bacterial infections such as cholecystitis, bacteremia, cholangitis and traveler’s diarrhea, as well as other clinical infections such as neonatal meningitis and pneumonia. Most Infections caused by Escherichia coli are relative easy to cure, however, hospital adapted strains of Escherichia coli are often multi-resistant and are able to cause life threatening infections.

What are you looking for?
By using this website, you agree to the use of Cookies to give you the best user experience.Ok